February 16, 2017 / 12:45 PM / in 8 months

BRIEF-Genocea reports Q4 loss per share $0.56

Feb 16 (Reuters) - Genocea Biosciences Inc :

* Genocea reports fourth quarter and year-end 2016 financial results

* Positive phase 2B clinical data confirm attractive profile for GEN-003; expected to start phase 3 program in 4Q 2017

* Neoantigen cancer vaccine program on track to file first IND by end of 2017

* Qtrly loss per share $0.56 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below